Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
7.35
-0.25 (-3.29%)
Jul 14, 2025, 5:29 PM CET
-61.66%
Market Cap 1.72B
Revenue (ttm) 6.00M
Net Income (ttm) -311.88M
Shares Out 234.61M
EPS (ttm) -1.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 224,700
Average Volume 265,087
Open 7.57
Previous Close 7.60
Day's Range 7.35 - 7.57
52-Week Range 6.09 - 19.17
Beta 0.38
RSI 39.73
Earnings Date Aug 22, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.